Sinopharm Chuankang Pharmaceutical Co. Ltd.

Primary objective: To evaluate the pharmacokinetic parameters of Hydroxychloroquine Sulfate Tablets (Specification: 0.2g) produced by Sinopharm Sichuan Kang Pharmaceutical Co., Ltd. and Hydroxychloroquine Sulfate Tablets (Trade name: Plaquenil®, Specification: 0.2g) certified by Sanofi-aventis Ireland Ltd. TIA SANOFI by using a randomized, open, single-dose, two-preparation, single-period, parallel-group trial design, and to evaluate the bioequivalence of the reference preparation and the test preparation under fasting and postprandial conditions. Secondary objective: To observe the safety of the test preparation and the reference preparation in healthy subjects.

Primary objective: To evaluate the pharmacokinetic parameters of tacrolimus capsules (specification: 1 mg) produced by Sinopharm Sichuan Kang Pharmaceutical Co., Ltd. and tacrolimus capsules (trade name: Prograf®/Prograf®, specification: 1 mg) certified by Astellas Pharma Co., Ltd. using a single-center, randomized, open, single-dose, four-period, completely repeated crossover design, and to evaluate the bioequivalence of the reference preparation and the test preparation under fasting and postprandial conditions. Secondary objective: To observe the safety of the test preparation and the reference preparation in healthy subjects.

Main purpose: Tacrolimus capsules (specification: 1 mg/capsule) developed by Sinopharm Sichuan Kang Pharmaceutical Co., Ltd. were used as the test preparation, and Tacrolimus capsules (specification: 1 mg/capsule) developed by Astellas Pharma Co., Ltd. were used as the reference preparation. According to the relevant provisions of the bioequivalence test, the bioequivalence of the two preparations in healthy subjects was investigated. Secondary purpose: To observe the safety of the test preparation and the reference preparation in healthy subjects.